1 / 132

Initiation of Antiretroviral Therapy

Initiation of Antiretroviral Therapy. Dr Appolinaire TIAM Technical Director EGPAF-Lesotho. When to Start Therapy?. Eligibility for ART Adults and Adolescents. Criteria for initiation in a specific population. Priority population for ART initiation. Those with very low CD4 counts (<200)

seoras
Download Presentation

Initiation of Antiretroviral Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Initiation of Antiretroviral Therapy Dr Appolinaire TIAM Technical Director EGPAF-Lesotho

  2. When to Start Therapy?

  3. Eligibility for ART Adults and Adolescents

  4. Criteria for initiation in a specific population

  5. Priority population for ART initiation • Those with very low CD4 counts (<200) • Children • Pregnant women • TB patients • Absence of CD4 lab should not delay ART initiation in those in need such as children aged <24months, adults or child stage 3 or 4.

  6. HAART and Survival Based on Initial CD4+ Cell Count 0.12 0.10 0.08 0.06 0.04 0.02 0.00 • Modeled data from ART Cohort Collaborative • 10,855 patients included • 934 progressed to AIDS or died • IDUs excluded from model Cumulative Probability of AIDS/Death According to CD4+ Count at Initiation of HAART 101-200 cells/mm3201-350 cells/mm3351-500 cells/mm3 Probability of AIDS or Death 3 0 4 5 1 2 Years Since Initiation of HAART Sterne J, et al. CROI 2006. Abstract 525.

  7. When to Start - Consensus • Symptomatic patients that WHO stage 3 or 4 • Treat all • Asymptomatic patients • CD4 Abs: ≤350/mm3 • Regardless of HIV-1-RNA level • When the patient is ready to commit

  8. The Initial Regimen

  9. First Line for Treatment Naive Adults and Adolescents

  10. Mode of Action

  11. Substitution in the first line • Co-infection with TB: D-D interaction btw NVP and Rifampicin so EFZ should be substituted for NVP. • For children<3 years of wt<10kgs, give NVP at 200mg/m2. • Severe toxicity grade 3 or 4.

  12. Severe toxicities and potential First line substitutions

  13. Side effects

  14. Adverse Effects of Antiretroviral Drugs • Do occur commonly • Can be a potential barrier to successful therapy • May lead to a reduction in the quality of life • May be an important cause of non-adherence to therapy • REMEMBER: Overall experience in the world has shown that ARV medications are very well tolerated by the vast majority of patients!

  15. Outline • Common side effect profiles of each ARV drug (grouped by class) • Serious and rare toxicities of each ARV drug • Recognition & Management strategies • Brief review of long-term complications of PI’s • Food requirements of ARV drugs • Summary / Conclusions

  16. Side Effects and Toxicities • Side effects are usually self-limited and not life-threatening, and usually resolve over a short period of time and with symptomatic support. Side effects usually occur early after ARV initiation. • Toxicities are more severe, potentially life-threatening effects of ARVs and can occur at anytime.

  17. Potential Toxicities of NRTI Class • AZT Zidovudine Retrovir™ • 3TC LamuvidineEpivir™ • DDI DidanosineVidex™ • D4T StavudineZerit™ • ABC AbacavirZiagen™

  18. AZT (Zidovudine) • Most common: • Nausea, vomiting, headaches, fatigue, myalgias • Common: • Macrocytosis -- not significant, but a marker for adherence • Serious: • Anemia and neutropenia • Myositis (elevated CPK) and myopathy • Lactic Acidosis • Other: • Darkening of skin, mucous membranes, nails

  19. AZT pigmentation (nail beds)

  20. AZT pigmentation of the mucosa

  21. AZT pigmentation(hard and soft palate)

  22. AZT Anemia • Modification of AZT therapy must be considered when patients have substantial drop in HB (< 7.0 gm/dL) or more than 25% decrease from their baseline. • AZT-induced anemia can occur as early as 2-4 weeks following initiation, but typically occurs after 4-12 weeks, but sometimes later.

  23. Severe AZT Anemia • If significant drop in HB from baseline: • STOP AZT  Substitute D4T for AZT • Transfuse if HB < 5.5 gm/dL • Do not treat with AZT again.

  24. 3TC (Lamivudine) • Common: • None (well-tolerated) • Less common: • Occasional nausea, headaches, vomiting, and diarrhea • Serious: • Pancreatitis (very rare)

  25. D4Tn(Stavudine) Contraindicated with AZT • Common side effects: • Peripheral neuropathy (up to 20%) • Uncommon: • Lethargy, myalgia, headache • Serious: • Liver toxicity, pancreatitis (rare), lactic acidosis (rare)

  26. DDI (Didanosine) • Common: • Nausea • Bloating • Diarrhoea • Peripheral neuropathy (up to 20%) • Serious: • Pancreatitis, optic neuritis

  27. ABC (Abacavir) • Common: • Hypersensitivity reaction • Serious: • Anaphylactic reaction • Death may occur

  28. Recognition of ARV drug inducedPeripheral Neuropathy • ARV drugs implicated: D4T > DDI > > AZT • Need to document presence of PN at baseline visit since HIV alone can cause significant PN, which often improves with ARV therapy. • Typical symptoms (parasthesia, numbness) • Usually in hands / feet (“stocking-glove distribution”) • As progresses, can cause loss of reflexes and vibratory sense • Important to assess how PN affects activities of daily living (walking, sleeping, working, etc.)

  29. Management of ARV drug inducedPeripheral Neuropathy • Mild/Moderate PN • Treat side effects and continue same regimen • Treat with amitriptyline (begin at 25 mgs), carbamazepine, phenyton, or gabapentin. • NOTE: [Need to document presence of PN at baseline visit since HIV alone can cause significant PN] • Severe PN • Discontinue causative ARV drugs (D4T and/or DDI) • May take weeks-months for symptoms to resolve even after discontinuing causative ARV drugs

  30. Recognition of ARV drug induced Pancreatitis • Symptoms of pancreatitis typically during first 1-6 months • Begins with abdominal pain, nausea and vomiting • More common with DDI, but also rarely reported with 3TC and D4T • Elevated amylase/lipase (asymptomatic hyperamylasemia may be due to parotid/salivary gland source).

  31. Management of ARV Drug induced Pancreatitis • Treat abdominal pain, nausea, vomiting. • Bowel rest with IVF’s (stop all ARVs, until pancreatitis resolves); consider imaging with abdominal ultrasound / CT scan. • Do not re-challenge with offending ARV(s) if pancreatitis is confirmed.

  32. Lactic Acidosis Syndrome • Entire NRTI class implicated: • Recently described / reported • Probably due to mitochondrial toxicity • Very rare • Presentation is very vague (fatigue, nausea, vomiting, abdominal pain, weight loss, malaise, dyspneoa, and motor weakness)

  33. Recognition of Lactic Acidosis Syndrome • Laboratory Clues: • Increased anion gap: Na – [Cl + CO2] • Increased lactic acid (check with a grey-top tube on ice), modest elevation in SGOT/SGPT, and low HCO3 • NOTE: If your lab is not able to perform routine HCO3 on U/E, can run heparinised blood specimen on blood gas analyzer) • Diagnosis: • Above symptoms with elevated lactate level (> 5.0 mmol/L in adults

  34. Management of Lactic Acidosis Syndrome • High mortality rate (60%) • Consider administering bicarbonate and vitamin supplements (riboflavin). • Discontinue all ART; administer NRTI-sparing HAART after patient recovers. Consult HIV specialist. • Recovery from elevated lactic acid levels may be prolonged.

  35. Efavirenz (EFV) • Nevirapine (NVP) Potential Toxicities of NNRTI Class

  36. EFV (Efavirenz) • Common (not class-related): • Central nervous system side effects • Headaches • Light-headedness • Confusion • Sleep disturbances (abnormally vivid dreams) • These side effects typically resolve within the first 14-21 days of treatment

  37. EFV (Efavirenz) • Serious (class-related): • Skin rash; progressing to Steven’s Johnson Syndrome • Hepatotoxicity • The above toxicities are less common with EFV than with NVP.

  38. EFV (Efavirenz) • EFV is the only ARV absolutely contra-indicated in pregnancy • Not recommended for use in women with child-bearing potential • Safe to administer with ATT medications

  39. EFV (Efavirenz) • Other possible side effects: • Lipodystrophy (body habitus changes) • Elevated triglycerides/cholesterol • Breast enlargement

  40. NVP (Nevirapine) • Common: • Cutaneous • Skin rash, reported up to 20%, usually appears in the first few weeks to months of therapy. • Progresses to Stevens-Johnson Syndrome (SJS) in < 1.0%. • Less Common: • Liver toxicity(more common than with EFV)

  41. Mild NVP Rash • Moderate maculopapular rash is typically on face, trunk, and/or extremities, with or without pruritus. • Usually appears within the first few weeks to months of therapy. • Treat with antihistamines, topical skin creams, and NOT systemic steroids. • Usually resolves within a few weeks. • Safe to continue NVP, but if patient is still on OD dose, do not dose escalate until rash resolves. • Advise patient to return if rash worsens or mucous membrane involvement appears.

  42. Severe NVP Rash (1) • Severe Hypersensitivity Reaction • SJS is quite rare, occurs within the first 6-8 weeks of ARV therapy, and can be fatal. • Treat with steroids and stop ALL ARV drugs until patient recovers, and do not re-challenge with NVP.

  43. Severe NVP Rash (2) • Any of the following signs/symptoms suggest impending SJS: • Fever • Conjunctivitis • Extensive, moist, peeling rash • Mucous membrane involvement (lip sores/ulcers/swelling, new vaginal lesions) • Patient appears unwell

  44. NVP-Related SJS

  45. Stevens-Johnson Syndrome

  46. Management of NVP-induced Severe Skin Reaction • Discontinue ARVs and all other medications • Treatment: • Prednisone (40-60 mgs, taper) • Chlorpheniramine • Brufen • Paracetamol • Close observation, realizing that patient may deteriorate over next 72-96 hours • After recovery, new ARV regimen may substitute EFV or NFV for NVP. Do not re-challenge with NVP.

  47. NNRTI Liver Toxicity • If LFT’s up to 2x upper limit of normal values: WATCH! • If LFT’s ≥ 5x upper limit of normal values: • Stop all medications, including ARVs, and monitor LFTs. • When LFTs have normalized, restart ARVs. • If previously on NVP, substitute EFV or NFV for NVP. • If previously on EFV, substitute NFV for EFV (do not use NVP).

  48. Practical Considerations with NVP Treatment • LFTs should be drawn at 2 week follow-up visit after initiation of NVP. • NVP: Need to monitor patients closely during first 6-8 weeks on ART. • If possible, try to avoid simultaneous initiation of NVP with other drugs having potential hepatotoxicity, eg., ATT, IPT, cotrimoxazole. • However, INH and cotrimoxazole may safely be used with NVP.

More Related